Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and hypofractionated radiotherapy in intermediate-risk localized prostate cancer
2015-004617-25Phase 2Active
- Sponsor
- Fundación Canaria de Investigación Sanitaria
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Fundación Canaria de Investigación Sanitaria. Started Feb 2017; status: active.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-004617-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004617-25.